Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Streptokinase for acute ischemic stroke with relationship to time of administration

Article Abstract:

The clot-dissolving drug streptokinase may reduce mortality rates in people who have a stroke but only if the drug is given shortly after symptoms develop. Researchers studied the use of streptokinase in 340 patients hospitalized with stroke. Streptokinase was associated with a worse outcome, but only in the patients who received the drug more than 3 hours after the stroke. The drug did not reduce mortality rates and actually raised the incidence of bleeding. There was a slight advantage in those patients who got the drug within 3 hours but this result must be confirmed in a larger study.

Author: Hankey, Graeme J., Rosen, David, Davis, Stephen M., Donnan, Geoffrey A., Chambers, Brian R., Gates, Peter C., McNeil, John J., Stewart-Wynne, Edward G., Tuck, Roger R.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1996

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Thrombolytic therapy with streptokinase in acute ischemic stroke

Article Abstract:

The clot-dissolving drug streptokinase appears to increase the mortality rate from acute stroke. Of 310 patients admitted to a hospital within 6 hours of their stroke, 156 were given an intravenous infusion of streptokinase and 154 were given a placebo. At 10 days, mortality rates were almost twice as high in those given streptokinase compared to those given a placebo. However, those who received streptokinase and survived recovered more function and were less disabled.

Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Aptiganel Hydrochloride in Acute Ischemic Stroke: A Randomized Controlled Trial. (Original Contribution)

Article Abstract:

The drug aptiganel does not benefit stroke patients and may even harm them, according to a study of 628 stroke patients. The patients who took the drug had higher mortality rates than those who took a placebo, or inactive substance. This drug blocks glutamate receptors in the brain.

Author: Albers, Gregory W., Goldstein, Larry B., Hall, David, Lesko, Lynna M.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Germany, Product information, Boehringer Ingelheim GmbH

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Drug therapy, Stroke (Disease), Stroke, Streptokinase
Similar abstracts:
  • Abstracts: Tissue plasminogen activator for acute ischemic stroke. Low-molecular-weight heparin for the treatment of acute ischemic stroke
  • Abstracts: False cultural assumptions: a bar to effective communication. Sold short
  • Abstracts: Career development for women in academic medicine: multiple interventions in a department of medicine. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study
  • Abstracts: Rapid testing for HIV antibody: a technology whose time has come. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection
  • Abstracts: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.